• FirefoxInstall the new Firefox »
  •  Dow Down0.58% Nasdaq Down0.26%

    Cytori Therapeutics, Inc. (CYTX)

    1.14 Down 0.06(5.00%) Mar 4, 4:00PM EST
    |Pre-Market : 1.18 Up 0.04 (3.51%) 8:00AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Cytori Therapeutics, Inc.
    3020 Callan Road
    San Diego, CA 92121
    United States - Map
    Phone: 858-458-0900
    Fax: 858-458-0994
    Website: http://www.cytori.com

    Index Membership:N/A
    Full Time Employees:115

    Business Summary 

    Cytori Therapeutics, Inc., a cell therapy company, develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. It primarily provides the Celution System, a tissue processing system that automates the process of digesting fat tissue, releasing the ADRCs. The company also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; and StemSource 900/MB, a research laboratory equipment. Its products also include Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, as well as soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury. In addition, Cytori Therapeutics, Inc. develops products in therapeutic areas, such as the treatment of thermal burns, and orthopedics and sports medicine indications, as well as specifically heart failure due to ischemic heart disease. The company markets its systems, instrumentations, and consumables directly, as well as through a network of distributors to hospitals, clinics, tissue banks, stem cell banking companies, and researchers performing investigator-initiated and funded studies worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cytori Therapeutics, Inc.

    Corporate Governance 
    Cytori Therapeutics, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 5. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 2; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Marc H. Hedrick M.D., 52
    Chief Exec. Officer, Pres and Director
    Dr. Steven Kesten M.D., 57
    Chief Medical Officer and Exec. VP
    Mr. Tiago Girão ,
    Chief Financial Officer and VP of Fin.
    Mr. John W. Townsend ,
    Chief Accounting Officer and Controller
    Dr. John K. Fraser Ph.D., 54
    Chief Scientist
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders